Elara Capital observes that Aurobindo Pharma has 14 biosimilars in the pipeline. The company has also filed 3 biosimilars for ...

Motilal Oswal is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1300 in its ...

Recent hiccups related to manufacturing plant issues and tariff uncertainties have led to volatility in earnings and, ...

Aurobindo Pharma Limited announced mixed performance during the quarter ended June 2025. The business reported a consolidated ...

Prabhudas Lilladher is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1300 in ...

Aurobindo Pharma's net profit fell 10.2 per cent Y-o-Y to ₹824 crore in Q1FY26, as against ₹918 crore in the same quarter ...

Aurobindo Pharma's consolidated net profit fell by 10.2% to ₹824 crore in Q1, despite a 4% increase in revenue driven by European and growth market sales.

Aurobindo Pharma reports a 10.2% YoY drop in Q1 FY26 PAT, citing API sales and US market revenue decline. The company's ...

Indian drugmaker Aurobindo Pharma reported a lower first-quarter profit on Monday, as expenses grew faster than revenue - stung by weak prices in the key U.S. market.

Shree Cements, Aurobindo Pharma, DLF, Siemens Energy, Bosch, and Marico among 192 companies to release earnings report today.

Mumbai: Aurobindo Pharma Limited on Monday reported a 10.2 per cent year-on-year (YoY) drop in consolidated net profit to Rs ...

Aurobindo Pharma reported a 10.2% YoY decline in Q1 net profit to ₹824.2 crore, missing CNBC-TV18 estimates. Revenue rose 4%, ...